Clinical Trial Detail

NCT ID NCT00565851
Title Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

fallopian tube cancer

peritoneal carcinoma

ovarian clear cell cystadenocarcinoma

ovarian serous cystadenocarcinoma

ovarian mucinous cystadenocarcinoma

malignant ovarian Brenner tumor

ovarian cancer

Therapies

Gemcitabine

Docetaxel + Paclitaxel

Carboplatin

Bevacizumab

Age Groups: adult

No variant requirements are available.